Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more
Diagnos Laboratorium Utama PT Tbk (DGNS) - Net Assets
Latest net assets as of June 2025: Rp194.00 Billion IDR
Based on the latest financial reports, Diagnos Laboratorium Utama PT Tbk (DGNS) has net assets worth Rp194.00 Billion IDR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp304.08 Billion) and total liabilities (Rp110.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp194.00 Billion |
| % of Total Assets | 63.8% |
| Annual Growth Rate | 79.87% |
| 5-Year Change | 97.98% |
| 10-Year Change | N/A |
| Growth Volatility | 118.02 |
Diagnos Laboratorium Utama PT Tbk - Net Assets Trend (2017–2024)
This chart illustrates how Diagnos Laboratorium Utama PT Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Diagnos Laboratorium Utama PT Tbk (2017–2024)
The table below shows the annual net assets of Diagnos Laboratorium Utama PT Tbk from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp196.13 Billion | +0.28% |
| 2023-12-31 | Rp195.59 Billion | -7.05% |
| 2022-12-31 | Rp210.43 Billion | +4.28% |
| 2021-12-31 | Rp201.80 Billion | +103.70% |
| 2020-12-31 | Rp99.07 Billion | +113.23% |
| 2019-12-31 | Rp46.46 Billion | +250.22% |
| 2018-12-31 | Rp13.27 Billion | +312.18% |
| 2017-12-31 | Rp3.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Diagnos Laboratorium Utama PT Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4339.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp132.27 Billion | 67.44% |
| Common Stock | Rp31.25 Billion | 15.93% |
| Other Comprehensive Income | Rp-4.09 Billion | -2.09% |
| Other Components | Rp36.71 Billion | 18.72% |
| Total Equity | Rp196.13 Billion | 100.00% |
Diagnos Laboratorium Utama PT Tbk Competitors by Market Cap
The table below lists competitors of Diagnos Laboratorium Utama PT Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sala @ Sathorn Property Fund
BK:SSPF
|
$4.37 Million |
|
Pure Energy Minerals Limited
OTCQB:PEMIF
|
$4.37 Million |
|
NSC Groupe SA
PA:ALNSC
|
$4.37 Million |
|
SimFabric S.A.
WAR:SIM
|
$4.37 Million |
|
Semac Consultants Limited
NSE:SEMAC
|
$4.36 Million |
|
AYRO Inc
NASDAQ:AYRO
|
$4.36 Million |
|
TPI Composites Inc
NASDAQ:TPIC
|
$4.36 Million |
|
ISCC FINTECH SPA
F:L7H
|
$4.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagnos Laboratorium Utama PT Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 195,590,420,000 to 196,132,242,000, a change of 541,822,000 (0.3%).
- Net income of 747,443,774 contributed positively to equity growth.
- Other comprehensive income decreased equity by 205,622,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp747.44 Million | +0.38% |
| Other Comprehensive Income | Rp-205.62 Million | -0.1% |
| Other Changes | Rp226.00 | +0.0% |
| Total Change | Rp- | 0.28% |
Book Value vs Market Value Analysis
This analysis compares Diagnos Laboratorium Utama PT Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 110.30x to 1.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Rp2.57 | Rp284.00 | x |
| 2018-12-31 | Rp10.61 | Rp284.00 | x |
| 2019-12-31 | Rp37.17 | Rp284.00 | x |
| 2020-12-31 | Rp79.25 | Rp284.00 | x |
| 2021-12-31 | Rp162.69 | Rp284.00 | x |
| 2022-12-31 | Rp168.34 | Rp284.00 | x |
| 2023-12-31 | Rp156.47 | Rp284.00 | x |
| 2024-12-31 | Rp156.91 | Rp284.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagnos Laboratorium Utama PT Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.46%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.53x
- Recent ROE (0.38%) is below the historical average (27.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 42.94% | 9.86% | 1.65x | 2.64x | Rp1.06 Billion |
| 2018 | 69.84% | 24.03% | 1.58x | 1.84x | Rp7.94 Billion |
| 2019 | 19.96% | 18.07% | 0.87x | 1.27x | Rp4.63 Billion |
| 2020 | 53.18% | 28.76% | 1.38x | 1.34x | Rp42.78 Billion |
| 2021 | 31.86% | 21.28% | 1.25x | 1.20x | Rp44.12 Billion |
| 2022 | 6.02% | 6.57% | 0.80x | 1.14x | Rp-8.38 Billion |
| 2023 | -6.98% | -9.37% | 0.54x | 1.39x | Rp-33.21 Billion |
| 2024 | 0.38% | 0.46% | 0.54x | 1.53x | Rp-18.87 Billion |
Industry Comparison
This section compares Diagnos Laboratorium Utama PT Tbk's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,267,266,642,861
- Average return on equity (ROE) among peers: 6.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagnos Laboratorium Utama PT Tbk (DGNS) | Rp194.00 Billion | 42.94% | 0.57x | $4.36 Million |
| Prodia Widyahusada Tbk PT (PRDA) | $1.27 Trillion | 6.95% | 0.44x | $37.52 Million |